Jiangsu Hengrui Pharmaceutical Co., Ltd. is a pharmaceutical and health enterprise engaged in pharmaceutical innovation and R & D, production and promotion of high-quality drugs. It was founded in 1970 and listed on the Shanghai Stock Exchange in 2000. As of the end of 2018, it has more than 20,000 employees worldwide. Is a well-known domestic supplier of anti-tumor drugs, surgical drugs and contrast agents, is also the national anti-tumor drug technology innovation industry-University-Research Alliance lead unit, has established the National Targeted Drug Engineering Technology Research Center, post-doctoral research workstation.
In May 2018, Forbes released the list of the Top 100 Most Innovative Companies in the World. There were 7 companies in China on the list, and Hengrui Medicine ranked 64th. In 2018, the company realized operating revenue of 17.42 billion yuan and tax revenue of 3 billion yuan.
In the practice of market competition, Hengrui Medicine adheres to innovation as the driving force to build core competitiveness. The company invests more than 10% of R & D funds in sales each year, and has R & D centers or branches in the United States, Europe, Japan and China. As of the end of 2018, the company's R & D team has more than 3,000 people, including more than 2,000 doctors, masters and more than 100 returnees. In recent years, the company has successively undertaken 36 national major special projects. Four innovative medicines, irexibub, apatinib, thiopefilgrastim injection, and pirlotinib, have been approved for marketing, and a batch of innovative medicines have been approved. It is under clinical development and there are several innovative drugs in clinical practice in the United States. The company has accumulatively applied for 655 domestic invention patents, has 147 domestically valid invention patents, 226 European, Japanese and other foreign authorized patents. Its proprietary core technology has won 2 second prizes for national scientific and technological progress, and 1 gold prize for Chinese patents.
Based on the business principles of "honesty and trustworthiness, quality first", Hengrui Medicine ranks among the best in the domestic market for anti-tumor drugs, surgical anesthesia drugs, specialty infusions and contrast agents. At present, the company has 17 preparations such as injections, oral preparations and inhalation anesthetics on the market in Europe, America and Japan, and has realized the large-scale sales of domestic injections in Europe, America and Japan.
Perseverance goes far, Rui Yi lives. Hengrui Medicine has always adhered to the concept of "scientific research-based, creating a healthy life", with the overall goal of building a Chinese multinational pharmaceutical group, strives for progress and innovation, and constantly achieves new breakthroughs and breakthroughs in corporate development.